10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.875.1999



# kir 6.1 Rabbit pAb

kir 6.1 Rabbit pAb Catalog # AP94753

#### **Product Information**

ApplicationWBReactivityHumanHostRabbitClonalityPolyclonalCalculated MW48 KDaPhysical StateLiquid

Immunogen KLH conjugated synthetic peptide derived from human kir 6.1

Epitope Specificity 61-160/424

**Isotype** IgG

**Purity** affinity purified by Protein A

Buffer SUBCELLULAR LOCATION

CIMIL A DITY

SIMILARITY

0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Membrane; Multi-pass membrane protein.

Belongs to the inward rectifier-type potassium channel (TC 1.A.2.1) family.

KCNJ8 subfamily.

**DISEASE**Note=Defects in KCNJ8 may be associated with susceptibility to J-wave

syndromes, a group of heart disorders characterized by early repolarization events as indicated by abnormal J-wave manifestation on electrocardiogram (ECG). The J point denotes the junction of the QRS complex and the ST segment on the ECG, marking the end of depolarization and the beginning of repolarization. An abnormal J wave is a deflection with a dome or hump morphology immediately following the QRS complex of the surface ECG. Examples of J-wave disorders are arrhythmias associated with an early repolarization pattern in the inferior or mid to lateral precordial leads, Brugada syndrome, some cases of idiopathic ventricular fibrillation (VF) with an early repolarization pattern in the inferior, inferolateral or global leads, as well as arrhythmias associated with hypothermia. Defects in KCNJ8 may be a cause of susceptibility to sudden infant death syndrome (SIDS) [MIM:272120]. SIDS is the sudden death of an infant younger than 1 year that remains unexplained after a thorough case investigation, including performance of a complete autopsy, examination of the death scene, and review of clinical history. Pathophysiologic mechanisms for SIDS may include respiratory dysfunction, cardiac dysrhythmias, cardiorespiratory instability, and inborn errors of metabolism, but definitive pathogenic mechanisms precipitating an

**Important Note** 

This product as supplied is intended for research use only, not for use in

human, therapeutic or diagnostic applications.

**Background Descriptions**This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow

infant sudden death remain elusive.

into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by external barium.

#### **Additional Information**

Target/Specificity Predominantly detected in fetal and adult heart.

**Dilution** WB=1:500-2000

**Format** 0.01M TBS(pH7.4) with 1% BSA, 0.09% (W/V) sodium azide and 50% Glyce

Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When **Storage** 


reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody

is stable for at least two weeks at 2-4 °C.


## **Background**

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

### **Images**



Sample: Heart(Rat) Lysate at 40 ug Primary: Anti- kir 6.1 (AP94753) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 48 kD Observed band size: 48 kD



Sample: Lane 1: Mouse Liver tissue lysates Lane 2: Mouse Cerebrum tissue lysates Lane 3: Rat Liver tissue lysates Lane 4: Rat Skin tissue lysates Lane 5: Rat Cerebrum tissue lysates Primary: Anti-kir 6.1 (AP94753) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 48 kDa Observed band size: 45 kDa

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.